Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

dehydroxymethylepoxyquinomicin

Known as: DHMEQ cpd 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
BACKGROUND Nuclear factor-kappaB regulates the expression of several genes involved in inflammation, the immune response… 
Highly Cited
2008
Highly Cited
2008
TRAIL promotes apoptotic tumor cell death; however, TRAIL-resistant tumors need to be sensitized to reverse resistance… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2007
Highly Cited
2007
PURPOSE To investigate the involvement of the renin-angiotensin system (RAS) and the nuclear factor (NF)-kappaB pathway with… 
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2007
Highly Cited
2007
Immunotherapy with rituximab (chimeric anti-CD20 monoclonal antibody, Rituxan), alone or in conjunction with chemotherapy, has… 
  • figure 3
  • figure 4
  • table 1
  • figure 5
  • figure 6
Highly Cited
2006
Highly Cited
2006
Previously, we designed and synthesized a new NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ). In the present… 
Highly Cited
2006
Highly Cited
2006
The BRAFV600E mutation is closely linked to tumorigenesis and malignant phenotype of papillary thyroid cancer. Signaling pathways… 
Highly Cited
2005
Highly Cited
2005
We previously designed and synthesized the new nuclear factor kappaB (NF-kappaB) inhibitor dehydroxymethylepoxyquinomicin (DHMEQ… 
Highly Cited
2005
Highly Cited
2005
Adult T-cell leukemia (ATL) is an aggressive neoplasm caused by human T-cell leukemia virus type I (HTLV-I). The nuclear… 
Highly Cited
2004
Highly Cited
2004
Purpose: The objective of the study was to determine the effects of a novel selective nuclear factor κB (NF-κB) inhibitor… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2002
Highly Cited
2002
We previously designed and synthesized an NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), that showed anti…